231 related articles for article (PubMed ID: 30143953)
21. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
Zou P; Tang R; Luo M
Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
24. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
25. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
26. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
28. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU
Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487
[TBL] [Abstract][Full Text] [Related]
29. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
[TBL] [Abstract][Full Text] [Related]
30. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
[TBL] [Abstract][Full Text] [Related]
31. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
32. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
33. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
34. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
37. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
38. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
39. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Bayle A; Besse B; Annereau M; Bonastre J
Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
[TBL] [Abstract][Full Text] [Related]
40. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]